WEBULL
WebtradeDownload

Is AptarGroup (ATR) Still Cheap As Sales Rise But Earnings Slip?

Simply Wall St · 2d ago

Why AptarGroup Earnings Matter For Investors

AptarGroup (ATR) has reported second quarter 2026 results that show higher sales alongside lower net income and earnings per share compared with a year earlier, putting the company’s margins in sharper focus for investors.

See our latest analysis for AptarGroup.

AptarGroup shares trade at $136.75, with an 8.52% 1 month share price return and a 9.30% 3 month share price return that suggest momentum has been building even though the 1 year total shareholder return is nearly flat at 0.20%.

If the latest earnings and buyback activity have you reviewing your watchlist, it can also be a good moment to broaden your search through 22 top founder-led companies

AptarGroup has rallied over the past quarter even as margins came under pressure in the latest results. Are investors already pricing in the key positives, or does the current valuation still leave clear upside potential?

Most Popular Narrative: 17.3% Undervalued

The most followed narrative values AptarGroup at $165.29 per share compared with the current $136.75 price, which puts a clear spotlight on future cash generation and profitability.

Ongoing investments in innovation, such as next-generation nasal and derma dispensing systems and expansion into active material sciences, are anticipated to capture share in both pharmaceuticals and high-growth dermacosmetic markets. This strengthens AptarGroup's market leadership and supports long-term top-line growth.

Read the complete narrative.

Curious what underpins that higher fair value for AptarGroup? The narrative leans on steadier revenue, firmer profit margins, and a richer future earnings multiple. The detailed playbook behind those assumptions sits inside the full narrative.

Result: Fair Value of $165.29 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, AptarGroup still carries real execution risk if elevated legal expenses persist or if weaker demand for emergency medicine and consumer healthcare products continues.

Find out about the key risks to this AptarGroup narrative.

Another View On AptarGroup Valuation

The first narrative focuses on future earnings and cash flow, with our model indicating a fair value of $187.12 and AptarGroup trading about 26.9% below that level today. On that basis the stock appears undervalued. However, how comfortable are you with the forecasts contained in that SWS DCF model?

Look into how the SWS DCF model arrives at its fair value.

ATR Discounted Cash Flow as at Aug 2026
ATR Discounted Cash Flow as at Aug 2026

Next Steps

After weighing both the upbeat and cautious signals around AptarGroup, it makes sense to check the underlying data yourself and move quickly while the information is fresh. To understand how the current story balances potential upsides with areas of concern, start with the 4 key rewards and 2 important warning signs

Looking for more investment ideas beyond AptarGroup?

If you are reassessing AptarGroup today, this is also a smart moment to widen your search and spot other opportunities before they move without you.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.